Rising cost of insulin: A deterrent to compliance in patients with diabetes mellitus

•The rise in burden of DM has led to an exponential increase in health care cost.•The ever-increasing cost of insulin results in various cost-saving behaviors and non-compliance.•An entangled triplet of cost, non-compliance, and poor glycemic control leads to further rise in cost of managing the DM.•The introduction of biosimilar insulin has enabled wider access of insulin with a reduced price (20–40%).•A patient-centered approach involving the patient, prescriber, and payer (if relevant) should be practiced.